Biotinylated Mouse SOST / Sclerostin Protein, Avitag™,His Tag (HPLC verified)

1/4
Cat. No. / Size
Price
Availability
Qty
SOT-M82E3-25ug
$415.00
SOT-M82E3-200ug
$1,880.00
SOT-M82E3
Sub-Total :
$ 0
0
Add to Cart
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
0
Add to Cart
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

SOST, VBCH

Source

Biotinylated Mouse SOST Protein, Avitag,His Tag (SOT-M82E3) is expressed from human 293 cells (HEK293). It contains AA Gln 24 - Tyr 211 (Accession # Q99P68).

Predicted N-terminus: Gly

Molecular Characterization

This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a polyhistidine tag.

The protein has a calculated MW of 24.7 kDa. The protein migrates as 33-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Protein Ratio

Passed as determined by the SABA assay / HABA assay / binding ELISA.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

Formulation

Supplied as 0.2 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

ACRO Scientific Leadership Award

Supporting the scientists driving cell & gene therapy forward

Apply Now